InMode Ltd. Announces Quarter 3 2026 Financial Performance and Updates Full-Year Outlook
InMode Ltd. (Nasdaq: INMD), a prominent global provider of cutting-edge medical technologies, has released its consolidated financial results for the third quarter of 2026. The company reported quarterly GAAP revenues of $92.1 million, which aligns closely with the $93.2 million recorded in the same quarter of the previous year. This news comes alongside a reaffirmation of its financial outlook for the entire fiscal year.
Q3 Revenue Breakdown:
Income and Earnings:
InMode reported a GAAP net income of $18.9 million, translating to $0.32 per diluted share. A year ago, the corresponding figures were $21.9 million and $0.34 per diluted share. Looking at non-GAAP income, the net stood at $21.9 million or $0.37 per diluted share, compared to $24.5 million and $0.38 per diluted share last year.
Operational Insights:
While total revenue was comparable to the previous year's figures, InMode noted that capital equipment revenues in both the U.S. and international markets remained stable when compared to the second quarter of 2026. Management has indicated that this stability is expected to continue as the year progresses. Moshik Itzkovich, the company’s Chief Financial Officer, highlighted the importance of disciplined execution and strategic investments, aiming to secure opportunities that support long-term growth.
As of September 30, 2026, InMode's financial position was robust, with total cash, cash equivalents, marketable securities, and short-term bank deposits amounting to $512.7 million. This financial stability offers the company a strong footing to navigate upcoming challenges and pursue growth strategies.
InMode management has reiterated its full-year financial guidance for 2026. Revenues are projected to range between $365 million and $375 million, with non-GAAP gross margins expected to fall between 74% and 76%. Additionally, management anticipates non-GAAP income from operations to fall between $68 million and $73 million, alongside earnings per diluted share estimated between $1.29 and $1.34. These forecasts are based on current assumptions and may be subject to adjustments.
Following the conclusion of the Special Committee's review, InMode is set to resume its investor relations activities. This includes re-engagement through investor conferences and analyst meetings. An earnings conference call is planned for early next year, which will coincide with the release of Q4 and full-year financial results.
As the geopolitical climate remains tense, particularly around regions such as Gaza and northern Israel, InMode's operations have not faced significant disruption as of now. The company is actively monitoring developments in these areas, assessing any potential ramifications for its operations.
InMode is known for its innovative medical technologies, specializing in devices that utilize advanced radio frequency technology. Its product offerings cater to various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. The company is dedicated to enhancing surgical procedures and improving existing treatments, leveraging its minimally invasive technologies to drive growth in the medical arena. For more information, visit www.inmodemd.com.
InMode's consistent performance amidst market challenges underscores its commitment to innovation and operational prowess. Stakeholders can remain hopeful as the company navigates through the complexities of the current business landscape while aiming for sustained growth in the future.
Key Financial Highlights
Q3 Revenue Breakdown:
- - Quarterly revenues broke down further with consumables and service contributing $19.3 million, reflecting a slight dip of 3% compared to Q3 2025.
- - Gross margins stood steady at 78%, consistent with the same quarter the prior year. However, GAAP operating margins took a hit, dropping from 22% in Q3 2025 to 19% in Q3 2026.
Income and Earnings:
InMode reported a GAAP net income of $18.9 million, translating to $0.32 per diluted share. A year ago, the corresponding figures were $21.9 million and $0.34 per diluted share. Looking at non-GAAP income, the net stood at $21.9 million or $0.37 per diluted share, compared to $24.5 million and $0.38 per diluted share last year.
Operational Insights:
While total revenue was comparable to the previous year's figures, InMode noted that capital equipment revenues in both the U.S. and international markets remained stable when compared to the second quarter of 2026. Management has indicated that this stability is expected to continue as the year progresses. Moshik Itzkovich, the company’s Chief Financial Officer, highlighted the importance of disciplined execution and strategic investments, aiming to secure opportunities that support long-term growth.
Financial Position
As of September 30, 2026, InMode's financial position was robust, with total cash, cash equivalents, marketable securities, and short-term bank deposits amounting to $512.7 million. This financial stability offers the company a strong footing to navigate upcoming challenges and pursue growth strategies.
Looking Ahead: 2026 Financial Outlook
InMode management has reiterated its full-year financial guidance for 2026. Revenues are projected to range between $365 million and $375 million, with non-GAAP gross margins expected to fall between 74% and 76%. Additionally, management anticipates non-GAAP income from operations to fall between $68 million and $73 million, alongside earnings per diluted share estimated between $1.29 and $1.34. These forecasts are based on current assumptions and may be subject to adjustments.
Investor Relations and Future Engagements
Following the conclusion of the Special Committee's review, InMode is set to resume its investor relations activities. This includes re-engagement through investor conferences and analyst meetings. An earnings conference call is planned for early next year, which will coincide with the release of Q4 and full-year financial results.
Current Affairs in Israel
As the geopolitical climate remains tense, particularly around regions such as Gaza and northern Israel, InMode's operations have not faced significant disruption as of now. The company is actively monitoring developments in these areas, assessing any potential ramifications for its operations.
About InMode
InMode is known for its innovative medical technologies, specializing in devices that utilize advanced radio frequency technology. Its product offerings cater to various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. The company is dedicated to enhancing surgical procedures and improving existing treatments, leveraging its minimally invasive technologies to drive growth in the medical arena. For more information, visit www.inmodemd.com.
InMode's consistent performance amidst market challenges underscores its commitment to innovation and operational prowess. Stakeholders can remain hopeful as the company navigates through the complexities of the current business landscape while aiming for sustained growth in the future.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.